YWYulu Wang

Yulu Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yulu Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immune‐Excluded Mucosal Melanoma: Spatial Mechanisms of Checkpoint Resistance and Biomarker‐Guided Therapeutic Opportunities

    by Kevin M. Truong‐Balderas, Rachel C. Chang, Claudia Lasalle, Meredith C. Rogers, Yulu Wang, Kyle T. Amber, Adrian P. Mansini

    Mucosal melanoma is a rare, aggressive melanoma subtype arising from melanocytes within mucosal surfaces of the head and neck, anorectal, gastrointestinal, and genitourinary tracts. Unlike ultraviolet‐driven cutaneous melanoma, mucosal melanoma has lower tumor mutational burden, fewer BRAF V600 alterations, greater structural genomic complexity, and recurrent drivers including mutations in KIT, NRAS, NF1, SF3B1, and copy‐number alterations. It is often diagnosed at advanced stages, recurs locally, disseminates early, and responds less favorably to immune checkpoint inhibition than cutaneous melanoma. Low neoantigen burden contributes to this resistance, but emerging evidence indicates that antitumor immunity is also shaped by spatially organized tumor‐immune interactions, site‐specific mucosal biology, suppressive myeloid and stromal programs, angiogenic signaling, and underexplored innate checkpoint pathways. Here, we review mucosal melanoma as a biologically distinct model of immune‐excluded melanoma, summarizing its clinical behavior, genomic architecture, immunotherapy outcomes, and mechanisms of checkpoint resistance, with emphasis on restricted intratumoral CD8‐positive T‐cell infiltration, macrophage‐ and stroma‐rich barriers, angiogenic remodeling, and candidate innate checkpoints including B7‐H3, CD24–Siglec‐10, CD47–SIRPα, and B7‐H6/NKp30. We further discuss how spatial and circulating biomarkers may support response‐adapted translational studies and define actionable immune states across mucosal melanoma sites.

  • Keratinocyte Autophagy in Inflammatory Dermatoses: Mechanisms, Disease‐Specific Programs and Therapeutic Opportunities

    by Yulu Wang, Kevin M. Truong‐Balderas, Yi Gao, Claudia Lasalle, Sabrina Schundler, Bethany E. Perez White, Kyle T. Amber, Adrian P. Mansini

    Autophagy is increasingly recognised as a regulator of epithelial stress adaptation in the skin, but its role in inflammatory dermatoses remains difficult to interpret because autophagy intersects with barrier biology, keratinocyte differentiation, immune signalling, intracellular trafficking and lysosomal degradation. Keratinocytes are immune‐competent epithelial cells that integrate cytokine exposure, oxidative stress, microbial sensing and tissue injury into inflammatory output. In this review, we synthesize evidence on keratinocyte autophagy as a disease‐dependent regulator of epidermal homeostasis and cutaneous inflammation. We summarize core autophagy machinery, selective autophagy programs relevant to epidermal differentiation and the interpretive value of autophagic flux and lysosomal competence. We then discuss how autophagy influences keratinocyte differentiation, organelle clearance, lipid handling, barrier support, inflammatory restraint and stress adaptation. Disease‐specific evidence is reviewed in psoriasis, AP1S3‐associated pustular autoinflammation, atopic dermatitis and vitiligo. Across these settings, keratinocyte autophagy cannot be classified as uniformly protective or pathogenic; its effects depend on inflammatory context, trafficking state, cell‐type‐specific outputs and the ability of lysosomes to complete degradation. We also consider lessons from other barrier epithelia, therapeutic implications and common methodological limitations. A keratinocyte‐centered, flux‐aware interpretation provides a framework for organizing disease‐specific autophagy biology and for designing more rigorous mechanistic studies in inflammatory dermatoses.

  • Phosphodiesterase-4 inhibitors in the treatment of hidradenitis suppurativa: a systematic review

    by Seyed Mohammad Vahabi, Elnaz Pourgholi, Claudia Lasalle, Haley Gainer, Yulu Wang, Kyle T. Amber

  • Open Access

    CD 24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target

    by Claudia Lasalle, Rachel C. Chang, Nicole C. Nowak, Yulu Wang, Alessio Giubellino, Kyle T. Amber, Adrian P. Mansini

    Immune checkpoint inhibitors have transformed the treatment of advanced melanoma, yet many patients develop primary or acquired resistance. Although most work has focused on adaptive checkpoints (PD‐1 and CTLA‐4), accumulating evidence implicates innate immune suppression and stem‐like, drug‐resistant melanoma cell states. CD24, a small, heavily glycosylated glycosylphosphatidylinositol (GPI)‐anchored surface protein, sits at the intersection of these processes and is emerging as a context‐dependent biomarker and potential mediator of aggressive, therapy‐resistant melanoma states. In this review, we synthesize evidence indicating that CD24 is both a tumour‐intrinsic and tumour‐extrinsic regulator in melanoma. We summarize the structure, glycosylation and regulation of CD24, then discuss its role in melanoma, supporting phenotypic plasticity, sustaining stem‐like populations and promoting resistance to BRAF‐targeted and cytotoxic therapies through SOX2/STAT3‐linked programmes. We then examine the CD24–Siglec‐10 axis as an innate immune checkpoint that suppresses macrophage and dendritic cell function, promotes immune‐excluded ‘cold’ tumour microenvironments and may shape responses to immunotherapy among CD24+ melanoma cells. We highlight CD24 in tumour tissue, blood and extracellular vesicles as potential biomarkers of prognosis and pathway activity, and review CD24‐axis interventions, including anti‐CD24 antibodies, Siglec‐10 antagonists and CD24‐targeted CAR‐T/CAR‐NK cells, with rational combinations alongside PD‐1/CTLA‐4 blockade and MAPK‐targeted therapy. We propose that biomarker‐driven trials targeting this axis could open a new front in melanoma immunotherapy.


  • Open Access

    The Secretome of Bullous Pemphigoid IgG ‐Treated Keratinocytes Induces a Pro‐Inflammatory Eosinophil Response

    by Adrian P. Mansini, Lei Bao, Krishan D. Chhiba, Jing Li, Yulu Wang, Haley Gainer, M. Allen McAlexander, Christopher McCrae, Christopher D. Nazaroff, Fei Li Kuang, et al.

    Bullous pemphigoid (BP) is an autoimmune blistering disease whereby the cutaneous antigens BP180 and BP230 are targeted by autoantibodies. Skin lesions in BP are characterized by an abundance of eosinophils. We recently demonstrated that the treatment of keratinocytes with antibodies from patients with BP induces a robust inflammatory response with release of numerous cytokines, chemokines, complement factors, and proteases. We thus questioned whether this keratinocyte inflammatory response was capable of directly inducing an inflammatory response in eosinophils. We therefore treated human eosinophils with conditioned media from keratinocytes treated with IgG from patients with BP (BP‐IgG), or healthy controls (control‐IgG) with or without supplemental IL‐5. Flow cytometry revealed upregulation of CD107a/CD107b, markers of degranulation, on eosinophils treated with supernatants from BP‐IgG relative to control‐IgG treated keratinocytes. A decrease in CCR3 and CD101 was also identified. Functional activity of eosinophils was confirmed by performing a multiplex immunoassay on eosinophil supernatants. This revealed significant upregulation IL‐6, IL‐8, LIF, TGFα, MCP‐4, MMP‐9, and MMP‐10. Supplemental IL‐5 did not appear to significantly influence these responses. Our data demonstrate that the inflammatory activation of keratinocytes by BP‐IgG affects eosinophils, driving phenotypic changes consistent with degranulation, as well as a pro‐inflammatory and proteolytic response.

  • Review of Low‐Dose Naltrexone for Hailey–Hailey Disease Suggests Lack of Benefit in Dose Escalation

    by Yulu Wang, Haley R. Gainer, Claudia Lasalle, Yue Qiu, Zhuoran Xu, Adrian P. Mansini, Kyle T. Amber